The latest announcement is out from BriaCell Therapeutics ( (TSE:BCT) ).
BriaCell Therapeutics Corp. announced the completion of a 15:1 share consolidation to maintain compliance with Nasdaq listing requirements. The consolidation reduces the outstanding common shares from over 44 million to approximately 2.95 million, with trading on the new basis beginning January 29, 2025, on both TSX and Nasdaq.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care.
YTD Price Performance: -30.49%
Average Trading Volume: 65,269
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$25.2M
For a thorough assessment of BCT stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com